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Abstract
Background: Studies in mice have shown that PPARα is an important regulator of lipid metabolism in liver and key
transcription factor involved in the adaptive response to fasting. However, much less is known about the role of
PPARα in human liver.
Methods: Here we set out to study the function of PPARα in human liver via analysis of whole genome gene
regulation in human liver slices treated with the PPARα agonist Wy14643.
Results: Quantitative PCR indicated that PPARα is well expressed in human liver and human liver slices and that the
classical PPARα targets PLIN2, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARα activation.
Transcriptomics analysis indicated that 617 genes were upregulated and 665 genes were downregulated by
PPARα activation (q value < 0.05). Many genes induced by PPARα activation were involved in lipid metabolism
(ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein
response, whereas most of the downregulated genes were involved in immune-related pathways. Among the
most highly repressed genes upon PPARα activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1,
CXCL6), interferon γ-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes
(e.g. TLR3, NOS2, and LCN2). Comparative analysis of gene regulation by Wy14643 between human liver slices
and primary human hepatocytes showed that down-regulation of gene expression by PPARα is much better captured
by liver slices as compared to primary hepatocytes. In particular, PPARα activation markedly suppressed immunity/
inflammation-related genes in human liver slices but not in primary hepatocytes. Finally, several putative new target
genes of PPARα were identified that were commonly induced by PPARα activation in the two human liver model
systems, including TSKU, RHOF, CA12 and VSIG10L.
Conclusion: Our paper demonstrates the suitability and superiority of human liver slices over primary
hepatocytes for studying the functional role of PPARα in human liver. Our data underscore the major role of PPARα in
regulation of hepatic lipid and xenobiotic metabolism in human liver and reveal a marked immuno-suppressive/
anti-inflammatory effect of PPARα in human liver slices that may be therapeutically relevant for non-alcoholic
fatty liver disease.
Keywords: Precision cut liver slices, PPARα, Human liver, Transcriptomics
* Correspondence: sander.kersten@wur.nl
1Nutrition, Metabolism and Genomics Group, Wageningen University,
Stippeneng 4, 6708 WE, Wageningen, The Netherlands
Full list of author information is available at the end of the article
© 2015 Janssen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Janssen et al. BMC Genomics  (2015) 16:760 
DOI 10.1186/s12864-015-1969-3
Background
The Peroxisome Proliferator Activated Receptors (PPARs)
represent an important group of receptors involved in me-
diating the pleiotropic effects of various environmental
contaminants, food components, and drugs [1]. PPARs
are members of the nuclear receptor superfamily and
induce the expression of numerous genes by functioning
as ligand-activated transcription factors. The ligands for
PPARs encompass a range of synthetic compounds and
endogenous lipids, including various fatty acids and eicos-
anoids. Three different PPAR subtypes can be distin-
guished: PPARα, PPARδ, and PPARγ, each characterized
by a distinct tissue expression profile and set of functions
[2, 3]. Multiple functions have been assigned to PPARδ,
including roles in inflammation, lipid metabolism and
cancer [4]. Due to its ubiquitous expression pattern and
diverse cellular actions, no single descriptor appropriately
captures the biological function of PPARδ. The PPARγ is
known as the key transcriptional regulator that drives adi-
pogenesis [5], the process by which fat cells differenti-
ate from pre-adipocytes into mature adipose cells.
Apart from adipocytes, PPARγ is also expressed in a lim-
ited number of other cell types where it exerts anti-
inflammatory actions and promotes lipid storage [6]. By
serving as the molecular target of the insulin-sensitizing
drugs pioglitazone and rosiglitazone, PPARγ is one of the
key receptors in the pharmacological treatment of type 2
diabetes [7].
PPARα is best known for its role in the liver, where
it acts as the master regulator of lipid metabolism, es-
pecially during fasting [8–10]. Fasting is associated with
dramatic changes in lipid handling in the liver, which is
coordinated by PPARα. Specifically, low and high through-
put gene expression analyses have demonstrated that
PPARα governs expression of numerous genes involved in
nearly every single aspect of lipid metabolism, including
fatty acid uptake, mitochondrial and peroxisomal fatty
acid oxidation, ketogenesis, and formation and breakdown
of triglycerides and lipid droplets [11].
Similar to other members of the PPAR family, PPARα is
activated by a range of different fatty acids and eicosanoids
[12–16]. In addition, PPARα serves as receptor for a di-
verse array of synthetic compounds collectively referred to
as peroxisome proliferators [17]. These include phthalates,
insecticides, herbicides, surfactants, organic solvents, and
hypolipidemic fibrate drugs. Fibrates have been used for
several decades mainly for their ability to lower circulating
triglycerides [18]. More recently, pharmacological target-
ing of PPARα has shown promise for the treatment of
non-alcoholic fatty liver disease. Specifically, the dual
PPARα/δ agonist GFT505 was shown to improve liver
dysfunction markers, decrease hepatic lipid accumulation,
and reduce inflammatory gene expression in liver in sev-
eral animal models of non-alcoholic fatty liver disease
(NAFLD) [19]. Furthermore, GFT505 treatment lowered
liver dysfunction markers and improved hepatic and per-
ipheral insulin sensitivity in human subjects [19, 20].
Most of our insights into the physiological, toxico-
logical and pharmacological role of PPARα has been de-
rived from experiments in animals and in particular
from rodent studies. These studies have revealed that
PPARα is not only involved in the adaptive response to
fasting but also mediates the hepatocarcinogenic effects
of peroxisome proliferators [21]. Whether PPARα exerts
similar functions in human liver has been the subject of
controversy [22], which has been fueled by the perceived
lack of effect of PPARα agonists on peroxisomal fatty
acid oxidation in humans [23], as well as due to the pre-
sumed low expression of PPARα in human liver [24].
However, more recent studies have partly refuted those
notions, showing that a) PPARα expression is similar in
mouse and human liver, b) in human hepatocytes PPARα
governs the expression of numerous genes in various lipid
metabolic pathways, including peroxisomal fatty acid oxi-
dation [25, 26].
Nevertheless, the absence of more complex human
model systems has hampered our ability to gain insight
into the molecular function of PPARα in human liver, in
particular with respect to target gene regulation. To
overcome this limitation, we collected precision cut liver
slices (PCLS) from human subjects and studied the ef-
fect of PPARα activation on gene expression using whole
genome expression profiling. In contrast to primary he-
patocytes, PCLS mimic the multi-cellularity and struc-
tural organization of whole liver and thus represent a
superior ex-vivo model system for human liver [27]. So
far the use of PCLS for the study of nuclear receptors and
specifically PPARα function has been limited [28–30].
Here we report the use of PCLS in combination with
whole genome gene expression profiling to gain insight
into PPARα-mediated gene regulation in human liver.
Methods
Collection of liver biopsies
In all patients a laparoscopic Roux-en-Y Gastric By-
pass was performed under general anesthesia as treatment
for their morbid obesity. Patients were instructed to fasten
for solid foods and liquids starting at the night before sur-
gery. During surgery a biopsy of the liver was obtained
with the help of ultrasound dissection (UltraCision®). The
biopsy was collected from the liver edge. The majority of
the liver biopsies collected (n = 15) were immediately fro-
zen in liquid nitrogen and stored at −80 °C. The liver bi-
opsies targeted for slicing (n = 4) were immediately placed
in ice-cold oxygenated Belzer UW Cold Storage Solution
(Bridge to Life Ltd, Columbia, SC, USA) and quickly
transferred to our laboratory for further processing of
PCLS. Only macroscopically healthy livers were used for
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slicing. Biopsies were provided by the biobank of the Rijn-
state hospital. Collection of biopsies for research purposes
into the biobank was approved by the local institutional
review board on behalf of the medical ethics review com-
mittee of the Radboud University Medical Centre. All pa-
tients signed informed consent for collection of the biopsy
prior to surgery. Donor characteristics of the livers used
for slicing are shown in Table 1.
Preparation and treatment of precision cut liver slices
PCLS were prepared and cultured as described previ-
ously [31]. 5 mm cylindrical liver cores were prepared
with a surgical biopsy punch and sectioned to 200 μm
slices using a Krumdieck tissue slicer (Alabama Research
and Development, Munford, AL, USA) filled with carbon-
ated KHB (pH 7.4, supplemented with 25 mM glucose).
Liver slices were incubated in William’s E Medium (Gibco,
Paisley, Scotland) supplemented with penicillin/strepto-
mycin in 6-well plates at 37 °C/5 % CO2/80 % O2 under
continuous shaking (70 rpm). Duplicate wells were used
per donor with 3 liver slices per well. After 1 hour the
media was replaced with fresh William’s E Medium in
the presence or absence of Wy14643 (100 μM) dis-
solved in dimethyl sulfoxide (DMSO, final concentra-
tion 0.1 %). This concentration was chosen based on
the affinity of human PPARα for Wy14643 [32]. After
24 h incubation, liver slices were snap-frozen in liquid
nitrogen and stored in −80 °C for RNA isolation.
Primary human hepatocytes
The treatment of primary human hepatocytes with
Wy14643 has been previously described [26]. Briefly,
human hepatocytes from six different donors were pur-
chased from Lonza (Verviers, Belgium). Hepatocytes were
isolated with two-step collagenase perfusion method. Cell
viability was over 80 %. The cells were incubated for 24 h
in the presence or absence of Wy14643 (50 μM) dissolved
in DMSO, followed by RNA isolation.
RNA isolation and qPCR
Total RNA was isolated using TRIzol reagent (Invitrogen).
RNA integrity number was found to be above 7.1 for all
samples suggesting that the human liver slices were of
good quality. The RNA integrity number is based on a
digital electropherogram generated using a Agilent bio-
analyzer. It describes the degree of degradation of RNA
with level 10 representing completely intact RNA. RNA
was reverse transcribed using a iScript cDNA Synthesis Kit
(Bio-Rad Laboratories BV, Veenendaal, The Netherlands).
Real-time PCR was carried out using SensiMiX (Bioline)
on a CFX 384 Bio-Rad thermal cycler (Bio-Rad). 36B4 was
used as housekeeping gene. Primer sequences used are
shown in Table 2.
Microarray analysis
Total RNA was purified with RNeasy Minikit columns
(Qiagen) and RNA quality was assessed using RNA 6000
Nano chips on the Agilent 2100 Bioanalyzer (Agilent
Technologies, Amsterdam, The Netherlands). Purified
RNA (100 ng) was labeled with the Ambion WT expres-
sion kit (Invitrogen) and hybridized to an Affymetrix
Human Gene 1.1 ST array plate (Affymetrix, Santa Clara,
CA). Hybridization, washing, and scanning were carried
out on an Affymetrix GeneTitan platform according to
the instruction by the manufacturer. Arrays were nor-
malized using the Robust Multiarray Average method
[33, 34]. Probe sets were defined according to Dai et al.
[35]. In this method probes are assigned to Entrez IDs
as an unique gene identifier. The P-value for the effect
of Wy14643 treatment were calculated using an
Intensity-Based Moderated T-statistic (IBMT) [36]. The
q-value was calculated as measure of significance for
false discovery rate [37]. The microarray data for the hu-
man liver slices were submitted to Gene Expression
Omnibus (GSE71731). The microarray data for the hu-
man primary hepatocytes have been previously submit-
ted to Gene Expression Omnibus (GSE17251).
Gene set enrichment analysis (GSEA) was used to find
enriched gene sets in the induced or suppressed genes
[38]. Genes were ranked based on the paired IBMT-
statistic and subsequently analyzed for over- or under-
representation in predefined gene sets derived from Gene
Ontology, KEGG, National Cancer Institute, PFAM,
Biocarta, Reactome and WikiPathways pathway databases.
Only gene sets consisting of more than 15 and fewer than
500 genes were taken into account. Statistical significance
of GSEA results was determined using 1000 permutations.
Table 1 Donor characteristics of livers used for slicing
Patient Gender Age (years) Body Mass Index (g/m2)
1 Female 34 41
2 Female 46 43
3 Female 39 35
4 Female 41 38
Table 2 Primer sequences used for qPCR
Primer Sequence
Name Forward Reverse
36B4 CGGGAAGGCTGTGGTGCTG GTGAACACAAAGCCCACATTCC
ANGPTL4 CACAGCCTGCAGACACAACTC GGAGGCCAAACTGGCTTTGC
PLIN2 ATGGCATCCGTTGCAGTTGAT GATGGTCTTCACACCGTTCTC
PDK4 TGGAGCATTTCTCGCGCTAC ACAGGCAATTCTTGTCGCAAA
CPT1A TCCAGTTGGCTTATCGTGGTG CTAACGAGGGGTCGATCTTGG
VLDLR GGTGAAAATGATTGTGACAGTGG GTGAACTCGTCGGGACTACA
Janssen et al. BMC Genomics  (2015) 16:760 Page 3 of 13
Results
First, we determined the relative expression level of
PPARα in PCLS in comparison with human liver. After
correcting for the housekeeping gene 36B4, mRNA levels
of PPARα in human PCLS after 24 h incubation were
about ten-fold lower as compared to snap-frozen human
liver biopsies (Fig. 1a). To verify that the human liver
slices maintain their ability to respond to PPARα acti-
vation, we exposed the PCLS to 100 μM Wy14643,
isolated total RNA and performed qPCR to determine
the expression of a number of well-established PPARα tar-
get genes, including PLIN2, VLDLR, ANGPTL4, CPT1A
and PDK4 (Fig. 1b). All PPARα target genes analyzed
showed significant induction following Wy14643 treat-
ment, indicating the validity of our model to study
PPARα-mediated gene regulation.
To study the effect of PPARα activation on whole gen-
ome gene expression, we performed microarray analysis.
Wy14643-induced changes in expression of the selected
PPARα target genes were very similar between the
0
1
2
3
4
5
6
ANGPTL4 PLIN2 PDK4 CPT1A VLDLR
F
o
ld
 c
h
an
g
e
DMSO
Wy14643
0
1
2
3
4
5
6
ANGPTL4 PLIN2 PDK4 CPT1A VLDLR
F
o
ld
 c
h
an
g
e
DMSO
Wy14643
qPCR
Microarray
* *
* *
*
*
* *
* *
C
0
20
40
60
80
100
120
hLiver hPCLS
R
el
at
iv
e 
ex
p
re
ss
io
n
   
   
P
PA
R
α 
(%
)
A
B
Fig. 1 Classical PPARα targets genes are robustly induced by PPARα activation in human PCLS. a Expression level of PPARα in human liver biopsies
(n = 15) and human PCLS (n = 5). b Gene expression changes of selected PPARα target genes in human PCLS in response to 24 h Wy14643 treatment
as determined by quantitative real-time PCR. c Gene expression changes of the same genes according to microarray. Error bars represent SEM. Asterisk
indicates statistically significant (P < 0.05, Student's t-test)
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microarray and qPCR analysis (Fig. 1c). Using a FDR q-
value of 0.05 as cut-off (IBMT regularised paired t-test),
the expression of 1282 genes (out of 19,654 genes on the
array) was found to be significantly altered by Wy14643
treatment, of which 617 genes were upregulated and 665
genes were downregulated. The top 25 of most signifi-
cantly induced genes, ranked according to statistical sig-
nificance, are shown in Fig. 2a. The full list is available as
Additional file 1. The list includes many well-known
PPARα target genes involved in lipid metabolism (e.g.
VLDLR, ACADVL, PLIN2, ANGPTL4, CPT1A), as well
as many other genes covering a wide variety of biological
functions. In addition, the list includes a number of genes
with unknown function. Figure 2b shows the top 25 of
most significantly repressed genes, many of which are re-
lated to immune function and inflammation. The full list
of significantly downregulated genes is available as Add-
itional file 2.
To gain better insight into the biological function of
genes regulated by PPARα activation in human liver
Fig. 2 Top 25 genes induced or repressed by Wy14643 in human PCLS. Heatmap showing gene expression changes of the top 25 most significantly
induced (a) and repressed (b) genes in human PCLS treated with Wy14643 for 24 h, as determined by microarray analysis. Genes were ranked based
on statistical significance in the form of q-value (IBMT regularised paired t-test). P1 to P4 represent the four human subjects that donated
a liver specimen for preparation of PCLS
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slices, we performed gene set enrichment analysis (GSEA).
Pathways related to lipid metabolism or directly involving
PPARα featured prominently among the gene sets induced
by Wy14643 (Fig. 3). Also, several gene sets induced by
Wy14643 were related to the unfolded protein response
and UPR signaling by IRE1α and XBP1. Finally, we ob-
served significant enrichment of genes related to oxida-
tive stress and xenobiotic/drug metabolism. Gene sets
downregulated by PPARα activation were all related to
immune function and inflammation, illustrating a po-
tent anti-inflammatory/immuno-suppressive action of
PPARα in human liver.
An important goal of the present work was to test the
suitability of liver slices as a model to study PPARα
dependent gene regulation and compare it with other
available model systems for human liver. To that end, we
compared the whole genome expression profiles of human
liver slices treated with Wy14643 with the expression
profiles of primary human hepatocytes treated with
Wy14643. The expression profiles of primary human
hepatocytes have been previously published but were
re-analyzed [26]. The primary human hepatocytes were
treated for the same duration and microarray analysis
was performed in the same laboratory on the same
microarray platform.
The comparative analysis between primary human he-
patocytes and human liver slices was performed on a
common gene set of 17,351 genes. Using a statistical
cut-off of P < 0.001 (IBMT regularised paired t-test)
combined with a fold-change cut-off of 1.2, we found
347 genes to be upregulated in human liver slices, as
compared to 121 genes in the hepatocytes (Fig. 4a), with
an overlap of 47 genes. Remarkably, whereas 401 genes
were downregulated by Wy14643 in the liver slices, only
25 genes were downregulated by Wy14643 in the human
hepatocytes, with an overlap of only 4 genes. The data
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indicate that the human liver slices are much more sen-
sitive towards especially downregulation of gene expres-
sion by Wy14643 as compared to human hepatocytes.
This notion was further supported by correlation ana-
lysis in the form of a scatter plot (Fig. 4b). The upper
right portion of the scatter plot was well filled (Fig. 4b),
reflecting common induction by Wy14643 in PCLS and
primary hepatocytes, including well-known PPARα tar-
gets such as FABP1, PLIN2, PDK4 and ANGPTL4. In
contrast, the lower left portion of the scatter plot was
much less filled (Fig. 4b), reflecting little agreement
between PCLS and primary hepatocytes with respect to
downregulation of gene expression by Wy14643. In fact,
many genes were markedly downregulated by Wy14643
in the liver slices but showed no change in expression in
the hepatocytes. Nearly all genes conforming to this type
of expression were involved in immune-related function,
as illustrated by the chemokines CXCL9, CXCL10, and
CXCL11. Interestingly, a number of genes was explicitly
induced by PPARα activation in primary hepatocytes but
not in liver slices, including FABP3 as well as CREB3L3,
a possible mediator of the stimulatory effects of PPARα
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Fig. 4 Comparative analysis of effect Wy14643 on gene expression in human PCLS and primary hepatocytes. a The number of differentially expressed
genes in human PCLS and human primary hepatocytes in response to 24 h Wy14643 treatment in a common geneset of 17,351 genes was calculated
based on a statistical significance cut-off of P < 0.001 (IBMT regularised paired t-test) and fold-change >1.20. Genes were separated according to up- or
down-regulation. b Correlation plot showing changes in gene expression in response to Wy14643 (expressed as signal log ratio) in human PCLS (x-axis)
and primary human hepatocytes (y-axis). Selected PPARα target genes commonly induced by Wy14643 in PCLS and hepatocytes are highlighted in
red. Selected inflammation-related genes specifically repressed by Wy14643 in PCLS are highlighted in blue. Selected lipid metabolism-related genes
specifically induced by Wy14643 in primary hepatocytes are highlighted in green. c Volcano plot showing relative changes in gene expression
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P-value, y-axis) for the PCLS and primary hepatocytes
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on hepatic gene expression [11]. Subsequent analysis by
Volcano plot confirmed the overall more pronounced ef-
fect of PPARα activation on gene expression in liver slices
as compared to primary hepatocytes and also corrobo-
rated the relatively minor down-regulation of gene expres-
sion by PPARα activation in primary hepatocytes (Fig. 4c).
To further investigate this observation, we took the
40 genes most highly induced or repressed by Wy14643
in the liver slices (P < 0.001 and ranked according to
fold-change) and studied the response to Wy14643 of
the same genes in the primary hepatocytes. Whereas
the majority of genes induced by Wy14643 in the liver
slices were also induced by Wy14643 in the hepatocytes
(Fig. 5a)—as illustrated by the common induction of
well-known targets such as FABP1, PLIN2, FADS1 and
ANGPTL4—few genes that were downregulated by
Wy14643 in liver slices were also consistently downreg-
ulated by Wy14643 in primary hepatocytes (Fig. 5b).
Also, the magnitude of gene suppression by Wy14643
was generally much less pronounced in primary hepa-
tocytes. Confirming the GSEA results, the majority of
the most highly repressed genes were related to im-
munity and inflammation, including the aforementioned
chemokines (CXCL9-11, CCL8, CX3CL1, CXCL6), inter-
feron γ-induced genes (IFITM1, IFIT1, IFIT2, IFIT3) and
other immune-related genes (TLR3, NOS2, and LCN2).
To further explore the similarity in gene regulation by
Wy14643 between PCLS and primary hepatocytes, we
Fig. 5 Comparative heatmap analysis of effect Wy14643 on gene expression in human PCLS and primary hepatocytes. Genes that were
statistically significantly regulated by Wy14643 in human PCLS (P < 0.001, IBMT regularised paired t-test) were ranked according to fold-change in
expression. The top 40 genes with highest fold-induction (a) or fold-repression (b) are shown. Expression changes of the same gene set in pri-
mary hepatocytes is shown in the right panel. P1 to P4 represent the four human subjects that donated a liver specimen for preparation of PCLS.
P5 to P10 represent the six human subjects that donated a liver specimen for preparation of human hepatocytes
Janssen et al. BMC Genomics  (2015) 16:760 Page 8 of 13
took the enriched genes within the positively or nega-
tively enriched gene sets “IRE1α activated chaperones”,
“metabolism of xenobiotics by cytochrome P450”, and
“Interferon alpha beta signaling” (Fig. 3), and compared
gene expression changes between PCLS and primary
hepatocytes. Induction of most genes that are part of
“metabolism of xenobiotics by cytochrome P450” was
more pronounced in PCLS than in primary hepatocytes
but reasonably well conserved between the two model sys-
tems (Fig. 6a). A limited number of genes (i.e. CYP2J2)
showed higher fold-inductions in the primary hepatocytes
as compared to PCLS. Induction of genes part of “IRE1α
activated chaperones” was generally less pronounced in
comparison with genes part of “metabolism of xenobiotics
by cytochrome P450”, and was relatively weakly conserved
between PCLS and primary hepatocytes (Fig. 6b). An ex-
ception is ACADVL. However, the inclusion of ACADVL
(very long chain acyl-CoA dehydrogenase = fatty acid oxi-
dation) within “IRE1α activated chaperones” may be ques-
tioned. Consistent with the other data showing potent
downregulation of immune- and inflammation-related
genes by PPARα activation in PCLS but not primary hepa-
tocytes, suppression of genes part of “Interferon alpha beta
signaling” was exclusively observed in PCLS (Fig. 6c).
Finally, we used the microarray data of the human
primary hepatocytes and human PCLS treated with
Wy14643 to generate a detailed gene map of known
and putative PPARα target genes involved in lipid
metabolic pathways (Fig. 7). The map illustrates that
regulation of bile acid synthesis and secretion, which
is a well-established PPARα target pathway in mouse,
was only evident in primary hepatocytes and not in liver
slices. Conversely, genes involved in fatty acid elongation
and desaturation were clearly induced by PPARα activa-
tion in human liver slices but not in primary hepatocytes.
Discussion
The main conclusion of our study is that induction of
gene expression by PPARα activation is generally well
captured and shows significant overlap between human
liver slices and primary human hepatocytes, showing
consistent upregulation of genes involved in lipid and
xenobiotic metabolism in the two model systems. In
contrast, downregulation of gene expression by PPARα
activation is almost exclusively observed in human liver
slices. A previous study comparing mouse primary hepa-
tocytes, mouse liver slices and mouse liver reached a
similar conclusion [30]. Overall, our data indicate that
human PCLS are a superior model to study PPARα-
dependent gene regulation and PPARα functions in hu-
man liver.
As indicated above, PPARα activation caused major
downregulation of gene expression in human liver slices
but not in primary hepatocytes. A key difference between
primary hepatocytes and liver slices is that the primary
hepatocyte culture consists of only hepatocytes, whereas
the liver slices contain other cell types, including stellate
cells and Kupffer cells. A large portion of the downregu-
lated genes and pathways in the liver slices was found to
be connected to the immune system. Genes that were
highly repressed upon PPARα activation included several
chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6),
interferon γ-induced genes (e.g. IFITM1, IFIT1, IFIT2,
IFIT3) and numerous other immune-related genes (e.g.
TLR3, NOS2, and LCN2). Downregulation of gene expres-
sion is unlikely to be mediated by PPARα present in non-
parenchymal cells, as PPARα expression in these cells is
very low [30, 39]. Instead we prefer a scenario in which
the immuno-suppressive action of PPARα activation in
hepatocytes is dependent on (inflammatory) signals em-
anating from non-parenchymal cells. Indeed, downreg-
ulation of inflammatory gene expression in primary
hepatocytes and mouse liver by PPARα activation is
sensitive to the presence of pro-inflammatory stimuli
[40, 41]. Previously, we and others already demonstrated
that Kupffer cells promote fat storage in hepatocytes by
releasing inflammatory signals such as IL-1β, causing
downregulation of PPARα gene expression [42, 43].
Overall, these data suggest that the full scope of func-
tions of PPARα in hepatocytes is critically dependent
on the interaction with other liver cell types. It is of
interest to note that recently the anti-inflammatory ac-
tion of PPARα in mouse liver was unequivocally attrib-
uted to the ability of PPARα to interact with other
transcription factor pathways—a property referred to as
transrepression—independent of the DNA-binding ability
of PPARα, as shown in the context of steatohepatitis [44].
Despite the clear clinical efficacy of fibrates towards
lowering of circulating triglycerides, the lack of per-
oxisome proliferation in human primary hepatocytes
following PPARα activation has fed the idea that
humans are largely insensitive to peroxisome-proliferator-
induced hepatic effects and that the functional role of
PPARα in human liver may be limited [45–47]. Subse-
quent whole genome expression profiling studies in pri-
mary human hepatocytes have mostly discounted these
notions [25, 26]. We found that PPARα is highly expressed
in human liver with Ct values ranging from 22 to 26,
which is similar to the values observed in mouse liver
(data not shown). Importantly, despite the markedly lower
expression of PPARα in human PCLS as compared to
human liver, activation of PPARα in PCLS caused pro-
nounced upregulation or downregulation of numerous
genes, including many known PPARα targets, strongly
supporting the functionality of PPARα in human PCLS
and giving strong credibility to an important in vivo role
of PPARα in human liver. Recently, it was found that
human liver PPARα gene expression correlates negatively
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with the severity of steatohepatitis and with measures of
insulin resistance. Furthermore, histological improvement
in a follow-up biopsy was associated with increased ex-
pression of PPARα and its target genes, suggesting that
PPARα is involved in and may be therapeutically targeted
for human steatohepatitis [48].
The majority of gene sets enriched among the upregu-
lated genes were related to lipid and xenobiotic metabol-
ism, which are well-established target pathways of
PPARα. Intriguingly, several highly enriched gene sets
were part of the unfolded protein response and IRE1α-
XBP1 signaling, two key factors involved in governing
UPR. Currently, there are no published data linking
PPARα to IRE1α-XBP1 signaling and regulation of UPR,
though it has been observed that PPARα is involved in
regulating proteome maintenance by inducing numerous
heat shock proteins [49]. Surprisingly, recently it was
demonstrated that IRE1α-XBP1 signaling leads to acti-
vation of PPARα via direct binding of XBP1s to the
promoter of PPARα, thereby stimulating mitochondrial β-
oxidation and ketogenesis [50]. Thus, there appear to be
reciprocal interactions between PPARα and UPR. The
wider biological framework for regulation of UPR requires
further clarification.
Our analysis reveals differential regulation of a number
of PPARα targets between liver slices and primary hepa-
tocytes. For instance, VNN1 was significantly upregu-
lated by PPARα activation in primary hepatocytes but
Fig. 7 Overview of regulation of lipid metabolism by PPARα in human liver. A detailed overview map was created of metabolic genes upregulated by
PPARα in human liver based on transcriptomics analysis of human PCLS and primary hepatocytes treated with Wy14643. Genes indicated in red are
significantly induced by Wy14643 in human PCLS and primary hepatocytes. Genes indicated in green are significantly induced by Wy14643 in human
PCLS but not primary hepatocytes. Genes indicated in blue are significantly induced by Wy14643 in human primary hepatocytes but not
PCLS. Statistical significance was determined by IBMT regularised paired t-test (P < 0.01)
(See figure on previous page.)
Fig. 6 Regulation of selected gene sets by Wy14643 in human PCLS and primary hepatocytes. Heatmap showing gene expression changes of
enriched genes that are part of the gene sets “metabolism of xenobiotics by cytochrome P450” (a), “IRE1a activated chaperones” (b), and “Interferon
alpha beta signaling” (c) in human PCLS and primary hepatocytes. P1 to P4 represent the four human subjects that donated a liver specimen
for preparation of PCLS. P5 to P10 represent the six human subjects that donated a liver specimen for preparation of human hepatocytes
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showed no change in expression in liver slices. Conversely,
expression of FADS2 was significantly increased in human
liver slices but showed no change in primary hepatocytes.
The differential regulation of specific PPARα target genes
by Wy14643 between primary hepatocytes and liver slices
may be a reflection of the different cellular context in the
two models systems, with non-hepatocytes potentially
exerting a stimulatory or inhibitory influence on PPARα-
dependent gene induction. However, it should be real-
ized that for a number of genes the seemingly differ-
ential regulation may reflect a quantitative difference
rather than a true qualitative difference. For example,
SLC25A20 was induced significantly by 1.58-fold in
primary hepatocytes as compared to a non-significant
1.34-fold induction in liver slices, barely missing the
statistical significance cut-off.
Our analysis yielded a number of relatively poorly
characterized genes that showed a pronounced and con-
sistent upregulation upon PPARα activation in the two
human liver model systems. These include TSKU, RHOF,
CA12 and VSIG10L. Interestingly, many genes that were
found to be induced by PPARα in early microarray ana-
lyses and which did not have an assigned function at the
time were later shown to be involved in some aspect of
lipid metabolism. Accordingly, it can be hypothesized that
the above mentioned genes as well as other poorly charac-
terized genes that are commonly induced by Wy14643 in
various liver model systems may be directly or indirectly
connected to lipid metabolism.
The comparative microarray analysis of the effect of
PPARα activation in primary human hepatocytes and
human liver slices is somewhat hampered by a number
of different factors, including the use of different types
of Affymetrix gene chips, different human donors, and
an unequal number of biological replicates per group.
However, treatments of liver slices and hepatocytes were
carried out for the same duration and with the same
PPARα agonist. Furthermore, RNA was isolated and la-
beled via the same technique, hybridizations were per-
formed on the same platform by the same technician,
and the microarray data were processed in parallel using
the same analysis methods.
On a final note, the data collected in this paper were
added to a publicly available overview map of known
(lipid) metabolic genes upregulated by PPARα in human
liver (accessible via: http://en.wikipedia.org/wiki/Peroxi-
some_proliferator-activated_receptor_alpha), which was
generated largely by using published transcriptome
datasets.
Conclusion
In conclusion, our paper demonstrates the suitability
and superiority of PCLS over primary human hepato-
cytes for studying the functional role of PPARα in
human liver. Our data underscore the major role of
PPARα in regulation of hepatic lipid and xenobiotic me-
tabolism and reveal a marked immuno-suppressive/anti-
inflammatory effect of PPARα in human liver that may
be therapeutically relevant for NAFLD. The data add to
our growing understanding of the critical role of PPARα
in gene regulation in human liver.
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